Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib

BACKGROUND: Hepatocellular carcinoma (HCC) represents the most common primary carcinoma of the liver. Most patients present with advanced or metastatic HCC at diagnosis and face a very limited prognosis. Systemic treatment with the tyrosine-kinase inhibitors sorafenib or lenvatinib is considered as...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Visc Med
Main Authors: Roderburg, Christoph, Berres, Marie-Luise, Wree, Alexander, Loosen, Sven H., Luedde, Tom, Trautwein, Christian
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2019
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597928/
https://ncbi.nlm.nih.gov/pubmed/31312649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497465
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki